# Allrock Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allrock-bio

- Industry: Biotechnology
- Headquarters: Natick, US
- Website: www.allrockbio.com/
- Total disclosed funding: $50M
- Latest round: Series A (Sep 16, 2025)
- Investors on record: 2

## About

Based in the US, Allrock Bio, Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for treating cardiopulmonary diseases, including pulmonary hypertension and interstitial lung diseases.Allrock Bio, Inc. specializes in biopharmaceutical development, having been founded in 2024 in Natick, US. The company successfully raised USD 50.00 mn in Series A funding in September 2025, co-led by Versant Ventures and Westlake Village BioPartners. The founder's history is not publicly detailed. The company has engaged in one significant deal to date.Allrock Bio specializes in the development and commercialization of therapeutics aimed at treating cardiopulmonary diseases, with a primary focus on conditions such as pulmonary hypertension and interstitial lung diseases. The company’s core product offerings center around innovative drug development strategies that harness advanced science and robust clinical trial planning to deliver impactful therapies addressing unmet medical needs. Their team collaborates with global experts to ensure these therapies are brought to market efficiently, targeting healthcare providers and institutions across North America and Europe, particularly for patients suffering from severe respiratory disorders.Allrock Bio generates revenue through a structured approach involving partnerships and B2B transactions within the biotechnology sector. The company’s revenue model is anchored on collaborations with pharmaceutical companies and healthcare organizations for drug development and commercialization, typically involving licensing agreements and milestone payments tied to successful development stages of their therapeutic products. The acquisition of CinCor Pharma by AstraZeneca for up to USD 1.8 bn reflects the potential value of Allrock Bio’s innovations in the market. By leveraging strategic alliances, the company establishes recurring revenue streams that support ongoing research and development, while its flagship therapeutic products are expected to command significant interest from healthcare providers and institutions globally.In September 2025, Allrock Bio, Inc. will utilize the recently raised USD 50.00 mn in Series A funding to advance clinical testing of its lead drug candidate addressing pulmonary hypertension and related lung diseases. The company aims to expand into new markets in North America and Europe by the end of 2026, introducing new therapeutic products designed to meet the needs of patients with severe respiratory disorders. Allrock Bio's strategic focus will be on enhancing its product pipeline and establishing partnerships that facilitate its growth objectives.

## Funding rounds

- Series A, Sep 16, 2025, $50M — Versant Ventures, Westlake Village BioPartners

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A